ITA-IMMUNO-PET: The Role of [18F]FDG PET/CT for Assessing Response to Immunotherapy in Patients with Some Solid Tumors.
Laura EvangelistaAndrea BianchiAlessio AnnovazziRosa SciutoSilvia Di TragliaMatteo BaucknehtFrancesco LanfranchiSilvia MorbelliAnna Giulia NappiCristina FerrariGiuseppe RubiniStefano PanareoLuca UrsoMirco BartolomeiDavide D'ArienzoTullio ValenteVirginia RossettiPaola CaroliFederica MatteucciDemetrio AricòMichelangelo BombaciDomenica CaponnettoFrancesco BertagnaDomenico AlbanoFrancesco DondiSara GusellaAlessandro SpimpoloCinzia CarriereMichele BalmaAmbra BuschiazzoRosj GallicchioGiovanni StortoLivia RuffiniVeronica CervatiRoberta Eufrasia LeddaAnna Rita CervinoLea CuppariMarta BureiGiuseppe TrifiròElisabetta BrugolaCarolina Arianna ZaniniAlessandra AlessiValentina FuocoEttore SeregniDesiree' DeandreisVirginia LiberiniAntonino Maria MoreciSalvatore IalunaSabina PulizziMaria Luisa De RiminiPublished in: Cancers (2023)
[18F]FDG PET/CT could have a role in the assessment of response to immunotherapy in patients with some solid tumors. It can provide prognostic information and thus contribute to a patient's appropriate treatment. Prospective randomized controlled trials are mandatory.